Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DART
2024-511140-37-00Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Metastasis-free survival. Started Apr 2024; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-511140-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511140-37-00.